# NERV catalysts: Minerva Neurosciences, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/nerv/catalysts

> Minerva Neurosciences, Inc. (NERV) has 3 upcoming catalysts. The next is the roluperidone primary completion, December 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Minerva Neurosciences, Inc. |
| Ticker | NERV (Nasdaq) |
| SEC CIK | 1598646 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/nerv |

## Cash runway

Cash $76.9M as of 2026-09-30; quarterly burn $8.1M; about 28.3 months of runway at that rate (XBRL company facts, accession 0001193125-26-451797).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2022 | [Roluperidone NDA/BLA submission](https://sec-api.dev/pdufa/roluperidone) | NERV | negative symptoms in schizophrenia | completed | "In August 2022, we submitted a New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") for our lead product candidate, roluperidone, for the treatment of negative symptoms in schizophrenia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1598646/000119312525265685/nerv-20250930.htm)) |
| April 27, 2023 | [Roluperidone NDA/BLA submission](https://sec-api.dev/pdufa/roluperidone) | NERV | negative symptoms in patients with schizophrenia | completed | "On April 27, 2023, the FDA filed our NDA for roluperidone following our request for formal dispute resolution and appeal of the refusal-to-file letter." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1598646/000119312526101117/nerv-20251231.htm)) |
| April 28, 2023 | [Roluperidone NDA/BLA acceptance](https://sec-api.dev/pdufa/roluperidone) | NERV |  | completed | "On April 28, 2023, the Compensation Committee of the Company's board of directors certified the achievement of a performance condition occurring upon FDA acceptance of the NDA for roluperidone." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1598646/000119312526451797/nerv-20260930.htm)) |
| February 26, 2024 | [Roluperidone PDUFA date](https://sec-api.dev/pdufa/roluperidone) | NERV |  | completed, complete response letter | "On May 8, 2023, we received confirmation from the FDA that the NDA for roluperidone has been assigned a standard review classification, and that the FDA has assigned a Prescription Drug User Fee Act ("PDUFA") goal date of February 26, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1598646/000095017025108840/nerv-20250630.htm)) |
| February 26, 2024 | [Roluperidone complete response letter (CRL)](https://sec-api.dev/pdufa/roluperidone) | NERV | negative symptoms in patients with schizophrenia | completed, complete response letter | "On February 26, 2024, the FDA issued a Complete Response Letter ("CRL") regarding our NDA for roluperidone." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1598646/000119312526451797/nerv-20260930.htm)) |
| February 26, 2024 | [Release (release) complete response letter (CRL)](https://sec-api.dev/pdufa/release) | NERV |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA217002_20240226.pdf%22)) |
| March 11, 2026 | [Minerva Neurosciences, Inc. earnings report](https://sec-api.dev/companies/nerv/catalysts) | NERV |  | completed | "Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1598646/000119312526101074/d825896dex991.htm)) |
| Q2 2026 | [Roluperidone trial start](https://sec-api.dev/pdufa/roluperidone) | NERV |  | scheduled | "Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1598646/000119312526101074/d825896dex991.htm)) |
| December 2027 | [Roluperidone primary completion](https://sec-api.dev/pdufa/roluperidone) | NERV | Negative Symptoms of Schizophrenia | scheduled | "NCT07565428 (Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Minerva Neurosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07565428)) |
| Dec 2027 to Mar 2028 | [Roluperidone topline data readout](https://sec-api.dev/pdufa/roluperidone) | NERV | Negative Symptoms of Schizophrenia | scheduled | "NCT07565428 (Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Minerva Neurosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07565428)) |
| 2H 2028 | [Roluperidone topline data readout](https://sec-api.dev/pdufa/roluperidone) | NERV |  | scheduled | "The topline data from Phase B is expected in 2H 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1598646/000119312526450877/d192598dex991.htm)) |

## Drugs

- [Roluperidone](https://sec-api.dev/pdufa/roluperidone): negative symptoms in schizophrenia, negative symptoms in patients with schizophrenia, Negative Symptoms of Schizophrenia

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/nerv/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NERV catalysts: Minerva Neurosciences, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/nerv/catalysts

```bibtex
@misc{secapidev_companies_nerv_catalysts_20261116,
  title        = {NERV catalysts: Minerva Neurosciences, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/nerv/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_nerv_catalysts_20261116","title":"NERV catalysts: Minerva Neurosciences, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/nerv/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
